

Seq ID no: 77 PXI XXT

10066151 Results

SEQ ID NO: 5

RESULT 8

US-08-396-479B-4
; Sequence 4, Application US/08396479B
; Patent No. 5612455
; GENERAL INFORMATION:
; APPLICANT: HOEY, Timothy
; TITLE OF INVENTION: NUCLEAR FACTORS AND BINDING ASSAY
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FLEHR, HOHBACH, TEST, ALBRITTON & HERBERT
; STREET: 4 Embarcadero Center, Suite 3400
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/396,479B
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Osman, Richard A
; REGISTRATION NUMBER: 36,627
; REFERENCE/DOCKET NUMBER: A-59450-1/RAO
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 494-8700
; TELEFAX: (415) 494-8771
; TELEX: 210 277299
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 716 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-396-479B-4

Query Match 100.0%; Score 30; DB 1; Length 716;
Best Local Similarity 100.0%; Pred. No. 62;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PRIEIT 6
|||||
Db 118 PRIEIT 123

RESULT 9

US-08-818-823-4
; Sequence 4, Application US/08818823
; Patent No. 5708158
; GENERAL INFORMATION:
; APPLICANT: HOEY, Timothy
; TITLE OF INVENTION: NUCLEAR FACTORS AND BINDING ASSAY
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FLEHR, HOHBACH, TEST, ALBRITTON & HERBERT
; STREET: 4 Embarcadero Center, Suite 3400
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk

```

; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/818,823
; FILING DATE: 14-MAR-1997
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/396,479
; FILING DATE: 02-MAR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Osman, Richard A
; REGISTRATION NUMBER: 36,627
; REFERENCE/DOCKET NUMBER: A-59450-1/RAO
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 494-8700
; TELEFAX: (415) 494-8771
; TELEX: 210 277299
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 716 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-818-823-4

```

```

Query Match          100.0%; Score 30; DB 1; Length 716;
Best Local Similarity 100.0%; Pred. No. 62;
Matches      6; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

QY      1 PRIET 6
        |||||
Db      118 PRIET 123

```

RESULT 10

```

US-09-037-190-38
; Sequence 38, Application US/09037190
; Patent No. 6096515
; GENERAL INFORMATION:
; APPLICANT: Crabtree, Gerald R.
; APPLICANT: No. 6096515throp, Jeffrey P.
; APPLICANT: Ho, Steffan M.
; TITLE OF INVENTION: NF-AT POLYPEPTIDES AND POLYNUCLEOTIDES
; NUMBER OF SEQUENCES: 52
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FOLEY, HOAG & ELIOT LLP
; STREET: One Post Office Square
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109-2170
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/037,190
; FILING DATE: 09-MAR-1998
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/260,174
; FILING DATE: 13-JUN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/124,981
; FILING DATE: 20-SEP-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Vincent, Matthew P.
; REGISTRATION NUMBER: 36,709
; REFERENCE/DOCKET NUMBER: APV-332.03

```

; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 617-832-1000
 ; TELEFAX: 617-832-7000
 ; INFORMATION FOR SEQ ID NO: 38:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 716 amino acids
 ; TYPE: amino acid
 ; STRANDEDNESS:
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: peptide
 US-09-037-190-38

Query Match 100.0%; Score 30; DB 3; Length 716;
 Best Local Similarity 100.0%; Pred. No. 62;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PRIET 6 |||||
 Db 118 PRIET 123

SEQ ID NO: 6

RESULT 8
 AAW02250
 ID AAW02250 standard; protein; 902 AA.
 XX
 AC AAW02250;
 XX
 DT 17-NOV-1996 (first entry)
 XX
 DE Human transcription factor NFAT3.
 XX
 KW Nuclear factor of activated T-cells; NFAT; NFAT3; transcription factor;
 KW cytokine; gene expression; binding assay; immune system disease; therapy;
 KW diagnosis.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Domain 397..686
 FT /label= Rel_domain
 XX
 PN WO9626959-A1.
 XX
 PD 06-SEP-1996.
 XX
 PF 04-MAR-1996; 96WO-US003113.
 XX
 PR 02-MAR-1995; 95US-00396479.
 XX
 PA (TULA-) TULARIK INC.
 XX
 PI Hoey T;
 XX
 DR WPI; 1996-412738/41.
 DR N-PSDB; AAT36868.
 XX
 PT DNA mol. encoding human nuclear factors of activated T cells - useful for
 PT screening potential therapeutic and diagnostic agents for immune system
 PT diseases.
 XX
 PS Claim 5; Page 43-47; 64pp; English.
 XX
 CC The amino acid sequence (AAW02250) of human nuclear factor of activated T
 CC -cells class 3, NFAT3, was deduced from an isolated cDNA clone
 CC (AAT36868). NFATs (see also AAW02248-49 and AAW02251-53) include
 CC regulators of cytokine gene expression that modulate immune system
 CC function. They have invariant rel domain peptides (see also AAW02254-55)
 CC and share at least 50% sequence identity in their rel domains.
 CC Recombinant NFATs, or NFAT fragments contg. at least part of the rel

CC domain, can be expressed in prokaryotic or eukaryotic host cells. They
CC are used in high-throughput screenings to identify agents useful in the
CC diagnosis or treatment of diseases associated with expression of a gene
CC modulated by a transcription complex contg. NFAT(s)

XX

SQ Sequence 902 AA;

Query Match 100.0%; Score 29; DB 2; Length 902;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PSIRIT 6
|||||
Db 114 PSIRIT 119

SEQ ID NO: 7

RESULT 1

US-09-550-115-1
; Sequence 1, Application US/09550115
; Patent No. 6780597
; GENERAL INFORMATION:
; APPLICANT: ARAI, KEN-ICHI
; APPLICANT: LIU, JIE
; TITLE OF INVENTION: NF-AT DERIVED POLYPEPTIDES THAT BIND CALCINEURIN AND
; TITLE OF INVENTION: USES THEREOF
; FILE REFERENCE: 084335/0120
; CURRENT APPLICATION NUMBER: US/09/550,115
; CURRENT FILING DATE: 2000-04-12
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-550-115-1

Query Match 100.0%; Score 31; DB 4; Length 119;
Best Local Similarity 100.0%; Pred. No. 5.6;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PSIQFT 6
|||||
Db 85 PSIQFT 90

RESULT 5

NFC3_MOUSE

ID NFC3_MOUSE STANDARD; PRT; 1075 AA.
AC P97305; Q60896;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Nuclear factor of activated T-cells, cytoplasmic 3 (T cell
DE transcription factor NFAT4) (NF-ATc3) (NF-AT4) (NFATx).
GN Name=Nfatc3; Synonyms=NFAT4;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A. (ISOFORM X1).
RC TISSUE=Thymus;
RX MEDLINE=95378239; PubMed=7650004;
RA Ho S.N., Thomas D.J., Timmerman L.A., Li X., Francke U.,
RA Crabtree G.R.;
RT "NFATc3, a lymphoid-specific NFATc family member that is calcium-
RT regulated and exhibits distinct DNA binding specificity.";
RL J. Biol. Chem. 270:19898-19907(1995).

RN [2]
 RP SEQUENCE OF 12-1075 FROM N.A. (ISOFORMS X1; X2 AND DELTA-X).
 RC TISSUE=Thymic lymphoma;
 RX MEDLINE=97170074; PubMed=9017603;
 RA Liu J., Koyano-Nakagawa N., Amasaki Y., Saito-Ohara F., Ikeuchi T.,
 RA Imai S.-I., Takano T., Arai N., Yokota T., Arai K.-I.;
 RT "Calcineurin-dependent nuclear translocation of a murine transcription
 factor NFATx: molecular cloning and functional characterization.";
 RL Mol. Biol. Cell 8:157-170(1997).
 RN [3]
 RP REVIEW.
 RX MEDLINE=99189746; PubMed=10089876;
 RA Crabtree G.R.;
 RT "Generic signals and specific outcomes: signaling through Ca2+,
 calcineurin, and NF-AT.";
 RL Cell 96:611-614(1999).
 CC -!- FUNCTION: Plays a role in the inducible expression of cytokine
 CC genes in T cells, especially in the induction of the IL-2 (By
 CC similarity).
 CC -!- SUBUNIT: Member of the multicomponent NFATC transcription complex
 CC that consists of at least two components, a pre-existing
 CC cytoplasmic component NFATC2 and an inducible nuclear component
 CC NFATC1. Other members such as NFATC4, NFATC3 or members of the
 CC activating protein-1 family, MAF, GATA4 and Cbp/p300 can also bind
 CC the complex. NFATC proteins bind to DNA as monomers.
 CC -!- SUBCELLULAR LOCATION: Cytoplasmic for the phosphorylated form and
 CC nuclear after activation that is controlled by calcineurin-
 CC mediated dephosphorylation. Rapid nuclear exit of NFATC is thought
 CC to be one mechanism by which cells distinguish between sustained
 CC and transient calcium signals. The subcellular localization of
 CC NFATC play a key role in the gene transcription.
 CC -!- ALTERNATIVE PRODUCTS:
 CC Event=Alternative splicing; Named isoforms=3;
 CC Name=X1;
 CC IsoId=P97305-1; Sequence=Displayed;
 CC Name=X2;
 CC IsoId=P97305-2; Sequence=VSP_005604;
 CC Name=Delta-X;
 CC IsoId=P97305-3; Sequence=VSP_005603;
 CC -!- TISSUE SPECIFICITY: Expressed in thymus. Weakly expressed in
 CC muscle, spleen and kidney. Also expressed in lymph node.
 CC -!- DOMAIN: Rel Similarity Domain (RSD) allows DNA-binding and
 CC cooperative interactions with AP1 factors (By similarity).
 CC -!- PTM: Phosphorylated by NFATC-kinase; dephosphorylated by
 CC calcineurin (By similarity).
 CC -!- SIMILARITY: Belongs to the Rel/Dorsal family.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; D85612; BAA12833.1; -.
 DR EMBL; U28807; AAA93249.1; -.
 DR HSSP; O95644; 1A66.
 DR TRANSFAC; T01949; -.
 DR MGD; MGI:103296; Nfatc3.

Query Match 100.0%; Score 31; DB 1; Length 1075;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PSIQFT 6
 |||||
 Db 109 PSIQFT 114

SEQ ID NO: 71

RESULT 8

AAW10130

ID AAW10130 standard; protein; 519 AA.

XX

AC AAW10130;

XX

DT 25-SEP-1997 (first entry)

XX

DE C-CAM1 (cell adhesion molecule).

XX

KW C-CAM; cell adhesion molecule; tumour suppressor; detection; treatment; cancer; prostate; breast; bladder; antisense; inhibit; immortal.

XX

OS Homo sapiens.

XX

PN WO9700954-A1.

XX

PD 09-JAN-1997.

XX

PF 21-JUN-1996; 96WO-US010696.

XX

PR 23-JUN-1995; 95US-00494622.

XX

PA (TEXA) UNIV TEXAS SYSTEM.

XX

PI Hsieh J, Lin S;

XX

DR WPI; 1997-087381/08.

DR N-PSDB; AAT58786.

XX

PT Expression constructs for C-CAM cell adhesion molecule - used for
PT expressing the C-CAM as a tumour suppressor for treating cancers or for
PT producing immortalised cells.

XX

PS Example 1; Page 110-112; 142pp; English.

XX

CC This sequence is C-CAM1 (a cell adhesion molecule). The C-CAM1 cDNA can
CC be used in expression constructs under the control of a promoter
CC functional in eukaryotic cells. C-CAM can act as a tumour suppressor, and
CC the expression constructs can be used for restoring C-CAM function in a
CC cell that lacks C-CAM. The constructs can also be used for the detection
CC and treatment of cancers, eg. prostate, breast or bladder cancer. The
CC expression constructs with the nucleic acid in an antisense orientation
CC can be used for inhibiting C-CAM function in a cell. They can be used for
CC immortalising such cells

XX

SQ Sequence 519 AA;

Query Match 100.0%; Score 29; DB 2; Length 519;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PSIQUIT 6
|||
Db 325 PSIQUIT 330

RESULT 10

AAW02251

ID AAW02251 standard; protein; 708 AA.

XX

AC AAW02251;

XX

DT 18-NOV-1996 (first entry)

XX

DE Human transcription factor NFAT4a.

XX

KW Nuclear factor of activated T-cells; NFAT; NFAT4a; transcription factor;

KW cytokine; gene expression; binding assay; immune system disease; therapy;
 KW diagnosis.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Protein 1. .699
 FT /note= "N-terminal sequence shared by NFAT4a, NFAT4b and
 FT NFAT4c"
 FT Domain 411. .702
 FT /label= Rel_domain
 XX
 PN WO9626959-A1.
 XX
 PD 06-SEP-1996.
 XX
 PF 04-MAR-1996; 96WO-US003113.
 XX
 PR 02-MAR-1995; 95US-00396479.
 XX
 PA (TULA-) TULARIK INC.
 XX
 PI Hoey T;
 XX
 DR WPI; 1996-412738/41.
 DR N-PSDB; AAT33677.
 XX
 PT DNA mol. encoding human nuclear factors of activated T cells - useful for
 PT screening potential therapeutic and diagnostic agents for immune system
 PT diseases.
 XX
 PS Claim 6; Page 52-54; 64pp; English.
 XX
 CC 4 Types of human nuclear factor of activated T-cells class 4, NFAT4a
 CC (AAW02251), NFAT4b and NFAT4c, result from alternative splicing
 CC downstream of the rel homology domain. The 3 types have identical N-
 CC terminal sequences, but C-terminal sequences differ for NFATb (AAW02252)
 CC and NFATc (AAW02253) from that for NFATa. NFATs (see also AAW02248-50)
 CC include regulators of cytokine gene expression that modulate immune
 CC system function. Recombinant NFATs, or NFAT fragments contg. the rel
 CC domain, can be expressed in prokaryotic or eukaryotic host cells. They
 CC are used in high- throughput screenings to identify agents useful in the
 CC diagnosis or treatment of diseases associated with expression of a gene
 CC modulated by a transcription complex contg. NFAT(s)
 XX
 SQ Sequence 708 AA;

Query Match 100.0%; Score 29; DB 2; Length 708;
 Best Local Similarity 100.0%; Pred. No. 6.5e+02;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PSIQIT 6
 |||||
 Db 109 PSIQIT 114